Format

Send to

Choose Destination
Curr Opin Genet Dev. 2010 Feb;20(1):87-90. doi: 10.1016/j.gde.2009.11.002. Epub 2009 Dec 16.

Targeting the PI3K signaling pathway in cancer.

Author information

1
Department of Medicine, Harvard Medical School, Boston, MA 02115, United States. kwok-kin_wong@dfci.harvard.edu

Abstract

The phosphoinositide 3-kinase (PI3K) pathway is activated in a variety of different human cancers, and inhibitors of this pathway are under active development as anti-cancer therapeutics. In this review, we discuss the data supporting the use of PI3K pathway inhibitors in genetically and clinically defined cancers. This review focuses on their efficacy as single agents and in combination with other targeted therapies, specifically those targeting the MEK-ERK signaling pathway.

PMID:
20006486
PMCID:
PMC2822054
DOI:
10.1016/j.gde.2009.11.002
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center